Expert perspectives on the current treatment paradigm for patients diagnosed with locally advanced or metastatic urothelial carcinoma.
Continuous Enzalutamide Proves Beneficial in Previously Treated mCRPC
November 9th 2022Results from a phase 3 study show that the continuous maintenance therapy of enzalutamide reduces the risk of disease progression in certain patients with metastatic castration resistant prostate cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512